Amgen
Pfizer sells Irish manufacturing facility to Amgen
March 14, 2011Manufacturing and Production Amgen, Dun Laoghaire, Ireland, Pfizer, pharma manufacturing, pharma manufacturing in Ireland
Amgen has come to the rescue of 280 workers whose jobs were threatened by the closure of a manufacturing facility …
Amgen signs $1 billion cancer biotech deal
January 25, 2011Research and Development Amgen, BioVex, OncoVEXGM-CSF, cancer vaccine
Amgen is set to pay $1 billion for US biotech firm BioVex, in the process gaining access to its novel …
Amgen plant will boost Boehringer Ingelheim’s US presence
January 21, 2011Manufacturing and Production Abgenix, Amgen, Boehringer Ingelheim, Vectibix, panitumumab, pharma manufacturing
Germany’s Boehringer Ingelheim has agreed to buy a development and manufacturing facility in Fremont, California, from leading biotechnology firm Amgen. …
Amgen aims for oncology expansion and a wider denosumab license
January 12, 2011Research and Development AMG- 479, AMG-386, Amgen, Cancer, Pancreatic cancer, denosumab, motasenib
Amgen is seeking to increase the use of its bone drug denosumab and further its reach into the oncology market, …
Amgen and Actelion meet to “talk takeover”
December 13, 2010Research and Development, Sales and Marketing Acelion, Amgen, pharma acquisitions, takeover
Amgen has met with Actelion to discuss a potential takeover but has not yet made a bid for the Swiss …
Denosumab approved for bone cancer use
November 19, 2010Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab
Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …
Glass flakes lead Amgen to order Epogen and Procrit recall
September 27, 2010Manufacturing and Production Amgen, Centocor Ortho Biotech, Epogen, Procrit, manufacturing compliance, recalls
Amgen has taken what it describes as a precautionary measure and recalled lots of two of its erythropoietin-based products Epogen …
Amgen’s Vectibix fails late stage trial
August 12, 2010Research and Development, Sales and Marketing Amgen, Vectibix, head and neck cancer
Amgen’s potential head and neck cancer treatment Vectibix has failed to meet its primary endpoint of improving overall survival in …
NICE halts Prolia appraisal
August 2, 2010Sales and Marketing Amgen, NICE, Prolia
NICE says it has been forced to terminate a review of Amgen’s bone density drug Prolia after the US biotech …
Novartis’ Jonathan Peacock moves to Amgen
July 23, 2010Sales and Marketing Amgen, appointment, sales and marketing
Amgen has appointed Jonathan Peacock executive VP and chief financial officer with effect from 1 September. He will move to …
Digital Pharma: Byte-sized roundup
July 19, 2010Medical Communications Amgen, Digital Pharma blog, EMA, Sermo, digital doctors, google, psoriasis
This week’s roundup includes EMA’s new look website, a psoriasis patient group’s e-commerce venture, Amgen’s online patient empowerment competition, changes …
Amgen’s Marc de Garidel elected EBE president
July 14, 2010Research and Development Amgen, European Biopharmaceutical Enterprises, appointment, research and development
Brussels-based industry association the European Biopharmaceutical Enterprises has elected Amgen’s Marc de Garidel as its new president. He will serve …
Prolia gets early thumbs up from NICE
June 18, 2010Sales and Marketing Amgen, NICE, Prolia
Amgen’s new treatment to prevent bone fractures caused by osteoporosis has been given preliminary approval from the UK’s cost effectiveness …
Digital Pharma: Amgen’s online village
June 16, 2010Medical Communications Amgen, ITP, community, disease awareness campaigns
Amgen has launched an online community for European healthcare professionals, patients and carers affected by autoimmune disease immune thrombycytopenia. Styled …
Amgen’s Prolia approved in Europe
June 1, 2010Sales and Marketing Amgen, Prolia
A blockbuster future is predicted for the osteoporosis treatment Prolia, with global sales predicted to reach $5 billion.European regulators have …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
